Your session is about to expire
← Back to Search
1 year follow-up for Cardiovascular Disease (CASCADE Trial)
CASCADE Trial Summary
This trial is designed to improve cardiovascular care for adult cancer survivors. The goal is to gather data to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.
- Cardiovascular Disease
- Cancer
CASCADE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CASCADE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research endeavor presently recruiting participants?
"At this time, the information hosted on clinicaltrials.gov reveals that recruitment for this trial is still taking place. The original posting was March 3rd 2022 and it has been reviewed as recently as November 15th of the same year."
What are the principal goals of this experiment?
"This clinical trial will be evaluating the diagnostic performance of NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%, over a 1 year post anthracycline therapy period. Secondary outcomes include assessing absolute change in LVEF and NT-pro BNP from baseline to one year after starting treatment, as well as determining any correlations between changes in these two variables."
How much support has this experiment gained from the public?
"Affirmative. Information hosted on clinicaltrials.gov corroborates that this medical trial, which was inaugurated on March 3rd 2022, is actively seeking participants. Around 200 individuals must be enrolled from a single research facility for the study to continue."
Are individuals under the age of 30 being accepted into this research initiative?
"The criteria for participation in this medical trial states that applicants must be 18 years or older, but cannot exceed the age of 99."
Are there any qualifications for participating in this trial?
"To qualify for this clinical trial, applicants must be between 18 and 99 years of age with a pre-existing cardiovascular condition. Additionally, they need to have been diagnosed breast cancer, lymphoma or sarcoma; plus they must either be currently undergoing or one year post completion of anthracycline therapy."
Share this study with friends
Copy Link
Messenger